Tolerability, Acceptance, and Utility of Intermittent CGM Use in Youth With Prediabetes
Continuous Glucose Monitors in the Management of Youth With Prediabetes
2 other identifiers
interventional
54
1 country
1
Brief Summary
We are evaluating whether intermittent use of continuous glucose monitors (CGMs) in addition to standard nutritional counseling and physical activity counseling is associated with improved metabolic health for youth with pre-diabetes (PD).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jun 2023
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 15, 2022
CompletedFirst Posted
Study publicly available on registry
August 17, 2022
CompletedStudy Start
First participant enrolled
June 5, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 15, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
May 15, 2025
CompletedResults Posted
Study results publicly available
June 17, 2026
CompletedJune 17, 2026
August 1, 2025
1.9 years
August 15, 2022
April 7, 2026
May 20, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
CGM Acceptability
Caregiver and patient acceptability of CGM use
6 months
Change in Measured % HbA1c From Baseline to 6-months
The difference in measured percentage of glycosylated hemoglobin (hemoglobin A1c) was obtained by subtracting the 6-month value from the baseline value for all subjects with paired data available. A negative result indicates a reduction (improvement) in hemoglobin A1c over the period.
6 months
Secondary Outcomes (4)
Change in HOMA-IR From Baseline to 6-months.
6 months
Change in Triglyceride, HDL, LDL, and Total Cholesterol From Baseline to 6-month
6 months
Changes in Liver Enzymes From Baseline to 6-months.
6 months
Glycemic Metrics
6 months
Study Arms (3)
CGM + Traditional Counseling
EXPERIMENTALSubjects in this arm will receive intermittent CGM to be used for 2-weeks each month for the 6-month study period. They will be required to wear a CGM during baseline, 3-month, and 6-month periods. Additional CGM sensors will be supplied for months 1, 2, 4, and 5 and will be optional. They will be provided with a Sworkit(R) account to monitor physical activity completed through the Sworkit(R) website/platform.
Control
ACTIVE COMPARATORSubjects in this arm will receive standard medical care for pre-diabetes. They will be provided with a Sworkit(R) account to monitor physical activity completed through the Sworkit(R) website/platform.
Caregivers of CGM + Traditional Counseling Group
NO INTERVENTIONCaregivers of those randomized to the intervention group were enrolled to give their feedback on the continuous glucose monitor via surveys at the 3-month and 6-month visits. Outside these surveys, there were no other inputs or interventions to this group.
Interventions
Subjects will be educated on use of Abbott Freestyle Libre 2 and educated on how daily activities impact glucose.
Subjects will be advised on recommendations for nutrition and activity goals for preventing progression of prediabetes.
Eligibility Criteria
You may qualify if:
- Age 11 or older
- English-speaking
- stable metformin dose for 1 month prior to enrollment or no metformin use
- baseline A1c of 5.7-6.4%
- BMI \> = 85% for age
You may not qualify if:
- BMI \< 85% for age
- chronic steroid use
- diagnosis of type 1 diabetes, type 2 diabetes, other forms of diabetes
- current or history of malignancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Children's of Alabama
Birmingham, Alabama, 35233, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Limitations and Caveats
CGM data is limited due to the number of participants with data available at baseline and 6-month follow-up. While fasting labs were requested, participants were not supervised for the 8-hours prior to their study visits, so confounding by non-fasting is possible.
Results Point of Contact
- Title
- Jessica Schmitt
- Organization
- University of Alabama at Birmingham
Study Officials
- PRINCIPAL INVESTIGATOR
Jessica A Schmitt, MD
University of Alabama at Birmingham
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
August 15, 2022
First Posted
August 17, 2022
Study Start
June 5, 2023
Primary Completion
May 15, 2025
Study Completion
May 15, 2025
Last Updated
June 17, 2026
Results First Posted
June 17, 2026
Record last verified: 2025-08
Data Sharing
- IPD Sharing
- Will not share